Drug Profile
Lutetium 177 rosopatamab tetraxetan - Telix Pharmaceuticals
Alternative Names: 177-Lu-DOTA-Rosopatamab - Telix Pharmaceuticals; 177Lu-DOTA-rosopatamab; 177Lu-DOTA-rosopatamb; 177Lu-DOTA-TLX591; 177Lu-DOTA-TLX591-CHO; 177Lu-TLX-591; Lutetium 177 DOTA rosopatamab - Telix Pharmaceuticals; Lutetium 177 rosopatamab - Telix Pharmaceuticals; TLX 591; TLX591t; TX591Latest Information Update: 24 Oct 2023
Price :
$50
*
At a glance
- Originator Telix Pharmaceuticals
- Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Prostate cancer
Most Recent Events
- 19 Oct 2023 Efficacy, and adverse events and pharmacokinetics data from a phase-I ProstACT-SELECT trial in Prostate cancer released by Telix Pharmaceuticals
- 18 Oct 2023 Telix Pharmaceuticals plans to file IND application for Phase-III PROSTACT trial in Prostate cancer (Metastatic disease, Hormone refractory, Second-line therapy or greater, Combination therapy) in the US in Q4 2023
- 18 Oct 2023 Telix Pharmaceuticals plans the phase III PROSTACT trial in Prostate cancer (Metastatic disease, Hormone refractory, Second-line therapy or greater, Combination therapy) in the US